Point-of-Care Glucose Testing Market Size, Share & Trends Analysis Report By Product (Accu-Chek Inform II, Freestyle Lite), By End-use (Hospital, Home Settings, Diagnostic Centers), By Region, And Segment Forecasts, 2022 - 2030

Report Overview

The global point-of-care glucose testing market size was valued at USD 3.1 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.1% from 2022 to 2030. The growing geriatric population, the ability of point-of-care (POC) diagnostic tests to deliver immediate results, thus providing improved patient care, and rising market penetration of Electronic Medical Records (EMRs) are among the high-impact rendering drivers of this market. The shortage of skilled staff, especially in the field of diagnostics, is also expected to increase the market penetration of glucose POC diagnostic products. The market is expected to gain momentum as the presence of diabetes increases the risk of mortality from COVID-19.

Thus, diabetes management is one of the key priorities among healthcare professionals to limit the mortality rate. According to a survey by the Diabetes Research Foundation, diabetes increases the risk of a fatal outcome by 50% among COVID-19 patients. The growing awareness about diabetes management, poor healthcare access, scarcity of healthcare professionals, and the highest global prevalence recorded in Asian countries are likely to increase the adoption of PoC glucose testing solutions. This, in turn, creates an opportunity to reduce the healthcare burden by improving patient outcomes.

The introduction of favorable regulatory policies aimed at promoting PoC glucose diagnostics is expected to serve as a high-impact rendering driver for the market. For example, in the U.S., the implementation of Clinical Laboratory Improvement Amendments (CLIA) is expected to boost usage rates during the forecast period. CLIA-waived tests are approved for use by healthcare providers operating in nontraditional laboratory sites, such as emergency rooms, physician offices, pharmacy clinics, health department clinics, and other healthcare facilities. The prevalence of diabetes is increasing worldwide, which is expanding the patient pool for the market.

Furthermore, the presence of unmet medical needs for diagnosis and management of diabetes and the increase in patient awareness are expected to boost the demand for POC diagnostics. According to the International Diabetes Federation, an estimated 537 million people had diabetes in 2021, and the number is projected to increase to 643 million by 2030 and 783 million by 2045. The healthcare industry is focusing on shorter hospital stays, better acute care, and the expansion of outlying surgical centers, which has consequently increased the demand for Short Turn-Around Testing (STAT). POC management solutions allow patients and healthcare providers to easily collect, share, and manage specimens to meet regulatory requirements.

Product Insights

The others product segment accounted for the largest share of more than 54% of the global revenue in 2021 and will continue expanding at a steady CAGR during the forecast period. POC monitoring devices allow home-based self-monitoring of blood glucose levels and help patients perform routine activities with ease. These devices are also being used in inpatient settings as they are easy to use while offering quick results. Several glucose meters have been launched in the industry to suffice the significant need for diabetes monitoring technologies across hospitals, clinics, and other medical settings.

The Accu-Chek Inform II segment held the second-largest share in 2021. The FreeStyle Lite product segment is expected to witness the fastest growth rate over the forecast period. FreeStyle Lite is offered by Abbott and is available in discreet size with an in-built portlight and backlight, which makes it user-friendly for patients with a busy lifestyle. The product is used for measuring blood sugar from samples collected from fingers, forearm, hand, upper arm, and thigh. It is recommended to use the FreeStyle Lite meter only with the FreeStyle control solution and testing strips as the usage of other control solutions and test strips can yield inaccurate results.

Regional Insights

North America dominated the global market in 2021. The regional market accounted for the largest share of over 40% of the overall revenue in the same year. It is expected to maintain its lead even during the forecast period. This region is home to several key market players, such as Abbott, Nova Biomedical, and Prodigy Diabetes Care, LLC. This has increased the availability of glucose testing products, thereby contributing to the revenue generation of the regional market. In addition, higher healthcare expenditure by governments on diabetes management is one of the factors responsible for the regional market growth.

The adoption of POC tests is rapidly increasing owing to their associated advantages, such as fast, easy, and mobile diagnosis and self-monitoring. These products facilitate diagnosis and monitoring for patients at hospitals, health assessment centers, clinics, and homes. Rapidly developing healthcare infrastructure and the high prevalence of diabetes are the key factors expected to drive the market in Asia Pacific. Furthermore, a rise in the adoption of miniaturized models and various measures being taken for reducing stays in hospitals and clinics are expected to boost the product demand. The adoption of POC glucose diagnostics in Operating Rooms (ORs), emergency rooms, Intensive Care Units (ICUs), path labs, and hospitals is expected to increase owing to the early and efficient delivery of results.

Key Companies & Market Share Insights

The market is highly fragmented with the presence of many large-, small-, and medium-scale vendors. Key players are focusing on multiple growth strategies, such as new product launches, expansions, collaborations, partnerships, and acquisitions. In June 2020, Tandem Diabetes Care and Abbott finalized an agreement to commercialize and develop an integrated diabetes solution that combines Tandem’s insulin delivery system and Abbott’s CGM technology. Some prominent players in the global point-of-care glucose testing market include:

• F. Hoffmann-La Roche Ltd.

• Abbott

• Nipro

• PlatInium Equity Advisors, LLC (Lifescan, Inc.)

• Nova Biomedical

• ACON Laboratories

• Trividia Health, Inc.

• Prodigy Diabetes Care, LLC

• Bayer AG/Ascensia Diabetes Care Holdings AG

• EKF Diagnostics

Point-of-Care Glucose Testing Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global point-of-care glucose testing market report on the basis of product, end use and region:

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Accu Check Aviva Meter

  • Onetouch Verio Flex

  • i-STAT

  • Freestyle Lite

  • Bayer CONTOUR Blood Glucose Monitoring System

  • True Metrix

  • Accu-Chek Inform II

  • StatStrip

  • Others

• End Use Outlook (Revenue, USD Million, 2018-2030)

  • Hospital

  • Home settings

  • Diagnostic centres

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Russia

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE